TIL
Tumor Infiltrating Lymphocytes
Shanghai Juncell TherapeuticsCell therapyEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 89/ 100
Competitive context
6 Active assets in the Tumor Infiltrating Lymphocytes cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
gc101 Shanghai Juncell Therapeutics | Phase 1/2 | B |
pd1-til Ruijin Hospital | Phase 1 | CC |
pd-1 knockout engineered t cells Ruijin Hospital | Phase 1 | CC |
Cyclophosphamide Shanghai Juncell Therapeutics | Early Phase 1 | C |
Fludarabine Shanghai Juncell Therapeutics | Early Phase 1 | C |
gc203 til Shanghai Juncell Therapeutics | Early Phase 1 | C |
Same molecule, other indications
TIL is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →